Page last updated: 2024-08-24

3-iodobenzylguanidine and Abdominal Obesity

3-iodobenzylguanidine has been researched along with Abdominal Obesity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abe, H; Dohi, T; Fuji, H; Higuchi, Y; Hikoso, S; Kida, H; Kitamura, T; Kojima, T; Kurakami, H; Mano, T; Mizuno, H; Nakagawa, Y; Nakatani, D; Oeun, B; Okada, K; Sakata, Y; Sato, T; Sotomi, Y; Suna, S; Sunaga, A; Uematsu, M; Yamada, T; Yasumura, Y	1

Other Studies

1 other study(ies) available for 3-iodobenzylguanidine and Abdominal Obesity

Article	Year
Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction. European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:2 Topics: 3-Iodobenzylguanidine; Female; Heart; Heart Failure; Humans; Iodine Radioisotopes; Male; Mediastinum; Obesity, Abdominal; Radiopharmaceuticals; Stroke Volume	2022

Article

Year

Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction.

European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:2

Topics: 3-Iodobenzylguanidine; Female; Heart; Heart Failure; Humans; Iodine Radioisotopes; Male; Mediastinum; Obesity, Abdominal; Radiopharmaceuticals; Stroke Volume

2022